PUMPKIN SEED OIL

INSTRUCTIONS FOR MEDICAL USE OF THE MEDICINAL PRODUCT PUMPKIN SEED OIL

Composition:

Active substance: 1 vial contains pumpkin seed oil (Cucurbitae semina oleum) 50 ml or 100 ml.

Pharmaceutical form. Oil.

Main physico-chemical properties: oily greenish-brown liquid with a characteristic odor. The presence of sediment is permissible.

Pharmacotherapeutic group.

Lipid-lowering agents. ATC Code C10AX.

Pharmacological properties.

Pharmacodynamics.

The drug contains a complex of biologically active substances from pumpkin seeds (carotenoids, tocopherols, phospholipids, phosphatides, flavonoids, vitamins B1, B2, C, P, PP, F, unsaturated, polyunsaturated, and monounsaturated fatty acids: palmitic, stearic, oleic, linolenic, linoleic, arachidonic), which determine its antioxidant, anti-atherosclerotic, anti-inflammatory, hepatoprotective, and choleretic effects. Due to phosphatidylcholine, which activates the enzyme lecithin-cholesterol acyltransferase, the drug converts free cholesterol into cholesterol esters, which do not participate in the development of atherosclerosis. In addition, phosphatidylcholine is incorporated into high-density lipoproteins, promoting accelerated transport of cholesterol into endothelial and platelet membranes and preventing their aggregation. Unsaturated fatty acids inhibit cholesterol absorption and facilitate fatty acid excretion. The drug improves the functional state of the biliary tract, alters the chemical composition of bile, exerts a mild choleretic effect, and reduces inflammatory processes in the epithelium of the biliary system. The drug reduces edema, improves microcirculation and epithelialization, provides protective effects on granulation tissue, and stimulates trophic and metabolic processes in tissues. The drug exerts antihypertensive effects, inhibits proliferation of prostate gland cells in benign prostatic hyperplasia, reduces the severity of inflammatory processes, and exhibits mild bacteriostatic properties.

Clinical characteristics.

Indications.

Prevention of cerebral and cardiac atherosclerosis, type IIa and IIb hyperlipidemia; prevention and complex treatment of benign prostatic hyperplasia stage I and II.

Contraindications.

Hypersensitivity to the drug. Concomitant use with antacids. Cholelithiasis. Pancreatitis.

Interaction with other medicinal products and other forms of interaction.

Antacids, H2-histamine receptor blockers, proton pump inhibitors, and bismuth-containing drugs reduce the absorption of pumpkin oil and the effectiveness of the medication.

When taking any other medicinal products concurrently, inform your physician.

Special precautions for use.

The drug is not recommended for patients with exacerbations of gastric and duodenal peptic ulcer, gastritis, esophagitis, duodenitis, colitis, and other diseases of the gastrointestinal mucosa in the stage of exacerbation.

The drug should be used with caution in patients prone to allergic reactions.

Due to the drug's moderate antithrombotic effect, it should be used cautiously in patients with hemophilia or other forms of hemorrhagic diathesis, as well as in patients taking anticoagulants. During treatment with this drug, laboratory monitoring of blood parameters should be performed at regular intervals (usually every 2–3 months) in such patients.

It is recommended to discontinue the drug at least 4 days prior to surgery or other surgical interventions.

If the drug is used for symptomatic treatment of benign prostatic hyperplasia, the condition should be monitored regularly (every 2–3 months).

The drug may alleviate symptoms caused by prostate enlargement, but does not affect the size of the prostate.

Use during pregnancy or breastfeeding.

The safety and efficacy of using Pumpkin seed oil during pregnancy or breastfeeding are unknown.

Ability to influence reaction rate while driving or operating machinery.

No influence.

Dosage and Administration

The product is taken orally.

Adults for the prevention of hyperlipidemia should take 1 teaspoon of oil twice daily, usually for 2 months, followed by ½ teaspoon twice daily. The duration of treatment depends on the severity and course of the disease, on average 6 months.

For benign prostatic hyperplasia, take 1 teaspoon of oil twice daily for an average of 4–5 weeks, followed by ½ teaspoon once daily. The duration of treatment is determined by the physician, usually 5 months.

Children.

The safety and efficacy of the product in children have not been established; therefore, the product should not be administered to children.

Overdose.

Symptoms: diarrhea, lethargy.

Treatment: discontinue use of the product if these symptoms occur. Symptomatic therapy.

Side effects.

With prolonged use, rare bowel disturbances and allergic reactions are possible.

If any adverse reactions occur, consult a physician!

Shelf life. 2 years.

Storage conditions.

Store in the original packaging at a temperature not exceeding 25 °C.

Keep out of reach of children.

Packaging.

50 ml or 100 ml in a bottle; 1 bottle per cardboard pack.

Availability.

Over-the-counter.

Manufacturer.

JSC "Lubnipharm".

Manufacturer's address and location of business activity.

16, Barvinkova St., Lubny, Poltava region, 37500, Ukraine.